ATE549404T1 - Verfahren zum screening eines transmembranenzymhemmstoffs - Google Patents

Verfahren zum screening eines transmembranenzymhemmstoffs

Info

Publication number
ATE549404T1
ATE549404T1 AT05790422T AT05790422T ATE549404T1 AT E549404 T1 ATE549404 T1 AT E549404T1 AT 05790422 T AT05790422 T AT 05790422T AT 05790422 T AT05790422 T AT 05790422T AT E549404 T1 ATE549404 T1 AT E549404T1
Authority
AT
Austria
Prior art keywords
transmembrane
enzyme
protein
region
inhibitor
Prior art date
Application number
AT05790422T
Other languages
English (en)
Inventor
Naoki Tarui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE549404T1 publication Critical patent/ATE549404T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05790422T 2004-10-01 2005-09-30 Verfahren zum screening eines transmembranenzymhemmstoffs ATE549404T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004290784 2004-10-01
PCT/JP2005/018587 WO2006038684A1 (ja) 2004-10-01 2005-09-30 膜貫通型酵素阻害物質のスクリーニング方法

Publications (1)

Publication Number Publication Date
ATE549404T1 true ATE549404T1 (de) 2012-03-15

Family

ID=36142754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05790422T ATE549404T1 (de) 2004-10-01 2005-09-30 Verfahren zum screening eines transmembranenzymhemmstoffs

Country Status (5)

Country Link
US (1) US20080220445A1 (de)
EP (1) EP1801232B1 (de)
JP (1) JP4778906B2 (de)
AT (1) ATE549404T1 (de)
WO (1) WO2006038684A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638070B1 (de) 2010-11-10 2016-10-19 F.Hoffmann-La Roche Ag Verfahren und zusammensetzungen zur immuntherapie bei nervenerkrankungen
US10882920B2 (en) 2014-11-19 2021-01-05 Genentech, Inc. Antibodies against BACE1 and use thereof for neural disease immunotherapy
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
CN107475260B (zh) * 2017-09-08 2020-12-04 东北师范大学 抑制大脑中Aβ累积的BACE1亚型的功能研发及应用
CN107523579A (zh) * 2017-09-08 2017-12-29 东北师范大学 促进大脑中Aβ累积的BACE1亚型的功能研发及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010569A1 (en) 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
CZ184194A3 (en) 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
WO1999043711A1 (en) * 1998-02-27 1999-09-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services G protein-coupled receptor antagonists
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
DE69941299D1 (de) * 1998-10-26 2009-10-01 Genzyme Corp Zusammensetzungen und verfahren zur behandlung der polyzystischen nierenkrankheit
JP2002037731A (ja) * 2000-05-19 2002-02-06 Takeda Chem Ind Ltd βセクレターゼ阻害剤
CN1251671C (zh) * 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
US6562783B2 (en) * 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
EP1459764A4 (de) * 2001-12-26 2006-08-16 Takeda Pharmaceutical Mittel zur behandlung von leichten erkennungsstörungen

Also Published As

Publication number Publication date
EP1801232A4 (de) 2008-12-10
WO2006038684A1 (ja) 2006-04-13
JPWO2006038684A1 (ja) 2008-05-15
US20080220445A1 (en) 2008-09-11
JP4778906B2 (ja) 2011-09-21
EP1801232B1 (de) 2012-03-14
EP1801232A1 (de) 2007-06-27

Similar Documents

Publication Publication Date Title
ATE496021T1 (de) Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2005082343A3 (en) Amines and amides for the treatment of diseases
ATE556711T1 (de) Verfahren zur verbesserung der hautqualität
AP1498A (en) Inhibitors of impdh enzyme.
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
PT966465E (pt) Inibidores do enzima imfdh
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
NO20074697L (no) Ikke-aromatisk, nitrogenholdig heterosyklisk-1-karboksylatester-pyridylderivat
BRPI0511111A (pt) compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
ATE506456T1 (de) Verfahren zur behandlung von lentivirusinfektionen
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
ATE549404T1 (de) Verfahren zum screening eines transmembranenzymhemmstoffs
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE476661T1 (de) Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörpers
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
MA29554B1 (fr) Nouveaux derives d'amide d'acide piperidine carboxylique
DK1539724T3 (da) Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet
EA200701852A1 (ru) Производные аминокислот